PD-L1 expression, when present on cancer cells, allows cancer cells to evade the immune surveillance and worsens the prognosis.8, 9, 10, 11 PD-L1 inhibitors have shown great potential in the treatment of various cancers, including subtypes of Angiosarcoma.12, 13, 14. Here, CD274 is linked to angiosarcoma.